BIOSIG TECHNOLOGIES INC (BSGM)
US09073N3008 - Common Stock
Taking everything into account, BSGM scores 1 out of 10 in our fundamental rating. BSGM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. BSGM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BSGM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
BSGM had negative earnings in the past year.
BSGM had a negative operating cash flow in the past year.
In the past 5 years BSGM always reported negative net income.
In the past 5 years BSGM always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -1589.24%, BSGM is doing worse than 98.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1589.24% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-828.31%
ROA(5y)-579.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BSGM has a better Gross Margin (66.67%) than 71.66% of its industry peers.
The Profit Margin and Operating Margin are not available for BSGM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.67% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BSGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
BSGM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BSGM has been increased compared to 5 years ago.
There is no outstanding debt for BSGM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
BSGM has an Altman-Z score of -270.16. This is a bad value and indicates that BSGM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -270.16, BSGM is doing worse than 96.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -270.16 |
ROIC/WACCN/A
WACC9.01%
2.3 Liquidity
A Current Ratio of 0.14 indicates that BSGM may have some problems paying its short term obligations.
BSGM has a Current ratio of 0.14. This is amonst the worse of the industry: BSGM underperforms 96.79% of its industry peers.
BSGM has a Quick Ratio of 0.14. This is a bad value and indicates that BSGM is not financially healthy enough and could expect problems in meeting its short term obligations.
BSGM has a worse Quick ratio (0.14) than 96.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.14 |
3. Growth
3.1 Past
BSGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.99%, which is quite impressive.
BSGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -93.71%.
EPS 1Y (TTM)62.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.25%
Revenue 1Y (TTM)-93.71%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 34.77% on average over the next years. This is a very strong growth
Based on estimates for the next years, BSGM will show a very strong growth in Revenue. The Revenue will grow by 123.61% on average per year.
EPS Next Y75.83%
EPS Next 2Y34.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y123.61%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
BSGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BSGM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BSGM's earnings are expected to grow with 34.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.77%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BSGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOSIG TECHNOLOGIES INC
NASDAQ:BSGM (11/4/2024, 8:00:02 PM)
After market: 1.57 +0.04 (+2.61%)1.53
+0.42 (+37.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap24.91M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1589.24% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.67% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.14 | ||
| Quick Ratio | 0.14 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)62.99%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y75.83%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-93.71%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y